New Issue | Current Topics in Medicinal Chemistry; Volume 19 Issue 31

ctmc.jpg

 

Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.

 

Articles from the journal: Current Topics in Medicinal Chemistry; Volume 19 Issue 31

 

 

 

For details on the articles, please visit this link: http://www.eurekaselect.com/node/615/current-topics-in-medicinal-chemistry/issue/19/2599/31/9575

New Issue | Current Topics in Medicinal Chemistry; Volume 19 Issue 25

 

ctmc.jpg

 

Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.

 

Articles from the journal: Current Topics in Medicinal Chemistry; Volume 19 Issue 25

For details on the articles, please visit this link: http://www.eurekaselect.com/node/615/current-topics-in-medicinal-chemistry/issue/19/2599/25/9462

Press Release | Bentham science’s latest book ‘Frontiers in Anti-Cancer Drug Discovery Volume 10’

 

This eBook is authored by Dr. Atta-ur-Rahman, published on June; this book is authored by Atta-ur-Rahman and M. Iqbal Choudhary; published on May 31, 2019. For Further Details, Please Visit : https://ebooks.benthamscience.com/book/9789811400711/

9789811400711-1.jpg

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The tenth volume of the series features chapters covering the following topics:

  • Challenges in the Management of Hepatoblastoma
  • The Emerging Role of Monocarboxylate Transporter-1 in Cancer
  • In-vitro Anti-Proliferative Assays and Techniques Used in Pre-Clinical Anti-Cancer Drug Discovery
  • Recent Advances in the Development of Mesoporous Anti-Cancer Drug Nanocarriers
  • Polyphenols and Cancer
  • Glioblastoma Multiforme
  • Cutting Edge Targeting Strategies Utilizing Nanotechnology in Breast Cancer Therapy
Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-bsl062019.php

New Issue | Letters in Drug Design & Discovery (Volume: 16, Issue: 6)

 

lddd.jpg

 

Letters in Drug Design & Discovery publishes letters, full-length/mini-reviews, highlights and guest edited thematic issues in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of latest Internet technology for both submission and review of manuscripts. The online journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery.

 

Articles from the journal: Letters in Drug Design & Discovery; Volume: 16, Issue: 6

 

For details on the articles, please visit this link: http://www.eurekaselect.com/node/634/letters-in-drug-design-discovery/issue/16/2491/6/9079

New Issue | Current Topics in Medicinal Chemistry; Volume: 19, Issue: 6

 

Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.

 

ctmc.jpg

 

Articles from the journal: Current Topics in Medicinal Chemistry; Volume: 19, Issue: 6

 

For details on the articles, please visit this link: http://www.eurekaselect.com/node/615/current-topics-in-medicinal-chemistry/issue/19/2599/6/9078

 

 

 

AIMS & SCOPE | Letters in Drug Design & Discovery

AIMS & SCOPE

Letters in Drug Design & Discovery publishes letters, full-length/mini-reviews, highlights and guest edited thematic issues in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of latest Internet technology for both submission and review of manuscripts. The online journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery. To learn more about the journal, please visit: https://benthamscience.com/journals/letters-in-drug-design-and-discovery/

 

lddd-flyer.jpg

Open Access Articles | Synthesis and Biological Evaluation of Some Novel Thiophene-bearing Quinazoline Derivatives as EGFR Inhibitors

Author(s): Min Zou, Bo Jin, Yanrong Liu, Huiping Chen, Zhuangli Zhang, Changzheng Zhang, Zhihong Zhao, Liyun Zheng*.

With the approval of gefitinib, erlotinib, afatinib, and osimertinib for clinical use, targeting Epidermal Growth Factor Receptor (EGFR) has been intensively pursued. Similar to most therapies, challenges related to the treatment resistance against these drugs have emerged over time, so new EGFR Tyrosine Kinase Inhibitors (TKIs) need to be developed. This study aimed to investigate the potential use of a series of thiophene-bearing quinazoline derivatives as EGFR inhibitors. We designed and synthesized nine quinazolin derivatives, among which five compounds (5e, 5f, 5g, 5h, and 5i) were reported for the first time. Read out full article here: http://www.eurekaselect.com/164334

 

Open acces

Article by Disease – “Insights into the Zinc-Dependent Deacetylase LpxC: Biochemical Properties and Inhibitor Design”

ARTICLE BY DISEASE ON “DIABETES”

Abstract:

The bacterial enzyme UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase (LpxC), catalyzing the first committed step of lipid A biosynthesis, represents a promising target in the development of novel antibiotics against Gram-negative bacteria. Structure, catalytic reaction mechanism and regulation of the Zn2+-dependent metalloamidase have been intensively investigated. The enzyme is required for growth and viability of Gram-negative bacteria, displays no sequence homology with any mammalian protein, but is highly conserved in Gram-negative bacteria, thus permitting the development of Gram-negative selective antibacterial agents with limited off-target effects. Several smallmolecule LpxC inhibitors have been developed, like the substrate analog TU-514 (12a), the aryloxazoline L-161,240 (13w), the sulfonamide BB-78485 (23a), the N-aroyl-L-threonine derivative CHIR-090 (24a), the sulfone-containing pyridone LpxC-3 (43e), and the uridine-based inhibitor 1-68A (47a), displaying diverse inhibitory and antibacterial activities. Most of these compounds share a Zn2+-binding hydroxamate moiety attached to a structural element addressing the hydrophobic tunnel or the UDP binding site. The butadiynyl derivative ACHN-975 (28) is the first LpxC inhibitor entering clinical trials.

Read more: http://www.eurekaselect.com/node/141238/article

%d bloggers like this: